Emsam Transdermal and Orkambi (Lumacaftor and Ivacaftor Tablets)
Determining the interaction of Emsam Transdermal and Orkambi (Lumacaftor and Ivacaftor Tablets) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Lumacaftor may alter the blood levels and effects of selegiline. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition worsens or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with lumacaftor may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of CYP450 3A4, 2B6, 2C19, 2C8, and/or 2C9. Lumacaftor is a potent inducer of CYP450 3A4 in vivo. Coadministration of lumacaftor with ivacaftor, a sensitive CYP450 3A4 substrate, decreased ivacaftor systemic exposure (AUC) by approximately 80%. In vitro, lumacaftor is an inducer of several other CYP450 isoenzymes including CYP450 2B6, 2C19, 2C8 and 2C9, although inhibition of the latter two isoenzymes has also been observed in vitro. Drugs that are substrates of CYP450 2C8 and 2C9 (e.g., sulfonylureas and other hypoglycemic agents, warfarin) may demonstrate decreased or increased exposures.
MANAGEMENT: Caution is advised when lumacaftor/ivacaftor is prescribed with drugs that undergo metabolism by CYP450 3A4, 2B6, 2C19, 2C8 and/or 2C9, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lumacaftor/ivacaftor is added to or withdrawn from therapy.
- "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: selegiline
Brand name: Emsam, Eldepryl, Zelapar
Synonyms: Emsam
Generic Name: ivacaftor / lumacaftor
Brand name: Orkambi
Synonyms: Orkambi
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Emsam Transdermal-Orlistat
- Emsam Transdermal-Ornex
- Emsam Transdermal-Ornex Maximum Strength
- Emsam Transdermal-Orphacol
- Emsam Transdermal-Orphenadrine
- Emsam Transdermal-Orphenadrine Citrate
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Emtricitabine
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Emtricitabine and tenofovir
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Emtricitabine and Tenofovir Alafenamide
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Emtricitabine and Tenofovir Disoproxil Fumarate
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Emtricitabine and Tenofovir Tablets
- Orkambi (Lumacaftor and Ivacaftor Tablets)-Emtricitabine Capsules